GlassScriptPhysician profile
Tariq Jamil
NPI 1649253287
$6,446.25
in general payments reported to CMS, 2019-2025
28 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $280 · 2021: $641 · 2022: $784 · 2023: $845 · 2024: $1,128 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,901.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $856.85 | 2019-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $697.04 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $689.53 | 2019-2025 | Farxiga, Tezspire, Breztri |
| Amgen INC. | $496.14 | 2019-2023 | Repatha |
| Medtronic, INC. | $438.07 | 2021-2025 | Pacific Xtreme, Hawkone |
| Janssen Pharmaceuticals, INC | $388.41 | 2019-2022 | |
| Glaxosmithkline, LLC. | $374.48 | 2024-2025 | Nucala |
| Actelion Pharmaceuticals US, INC. | $371.63 | 2024-2025 | Uptravi, Opsumit |
| Pfizer INC. | $345.81 | 2020-2025 | |
| Abbott Laboratories | $228.85 | 2021-2025 | Esprit, Thoratec Heartmate 3 Lvas Implant Kit |
| Philips North America LLC | $210.42 | 2023-2025 | Ecc Solutions, (Ck7) Extended Holter |
| Lexicon Pharmaceuticals, INC. | $160.37 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.77 | 2019-2024 | Jardiance |
| Phathom Pharmaceuticals, INC. | $149.18 | 2025 | Voquezna |
| Insmed, INC. | $124.93 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.82 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $108.14 | 2019-2023 | |
| Boston Scientific Corporation | $92.00 | 2019-2023 | Watchman Flx |
| Amarin Pharma, INC. | $81.53 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $77.54 | 2023-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $76.16 | 2021-2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $53.84 | 2022 | |
| Atricure, INC. | $48.64 | 2019 | |
| Gilead Sciences, INC. | $25.00 | 2019 | |
| Vifor Pharma, INC. | $22.92 | 2019 | |
| Preventice Services, LLC | $20.59 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.92 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.